Graybug Vision and CalciMedica to merge and focus on the development of Auxora.
Graybug Vision, Inc. and CalciMedica Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction
The combined company will focus on further developing CalciMedica’s lead product candidate Auxora, a proprietary, intravenous-formulated, small molecule calcium-release activated calcium (CRAC) channel inhibitor, to treat life-threatening inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure (AHRF), for which there are no currently approved therapies. Auxora, which modulates the immune response and protects against tissue cell injury, has been studied in four completed efficacy clinical trials, demonstrating positive and consistent clinical results, as well as a favorable safety profile. Subject to each company’s stockholder approval, the combined company is expected to trade on the Nasdaq Global Market.
Related news and insights
Merck Inc., and Imago BioSciences, Inc. announced that the companies have entered into a definitive agreement under which Merck Inc., through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion
Indivior PLC and Opiant Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration of $20.00 per share, in cash (approximately $145 million in aggregate), plus up to $8.00 per share in contingent value rights that may become payable in the event that certain net revenue milestones are achieved during the relevant seven-year period by OPNT 003 after its approval and launch